Skip to content

US · AUPH · BIOTECHNOLOGY

Aurinia Pharmaceuticals Inc. (AUPH) intrinsic value and stock valuation

$14.70as of 2026-11-21 · Mkt cap 2.04B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aurinia Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values AUPH with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from AUPH’s statements →

Aurinia Pharmaceuticals Inc. Graham Number

Graham Number: $14.42d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Edmonton, AB T5L 4S6 auriniapharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$283.1M+41.4% 5y CAGRd
20112025
Net income
$287.2M
20112025
Free cash flow
$135.4M
20112025
Total equity
$581.3M+7.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$283.1M$235.1M$175.5M$134M$45.6M
Operating income$104.9M-$-4.69M-$-91.69M-$-111.47M-$-180.74M
Net income$287.2M$5.75M-$-78.02M-$-108.18M-$-180.97M
EPSd$2.07M$39.3K-$-544.68K-$-762.31K-$-1.4M
Operating cash flow$135.7M$44.4M-$-33.46M-$-79.53M-$-157.69M
Capital expenditure-$-250K-$-280K-$-720K-$-290K-$-1.5M
Free cash flow$135.4M$44.1M-$-34.18M-$-79.82M-$-159.19M
Total assets$751.6M$550.6M$548.1M$470.9M$543.4M
Total debt$74.8M$79.4M$97.6M$8.09M$8.74M
Net debt-$-5.4M-$-4.06M$48.7M-$-86.08M-$-223.16M
Total equity$581.3M$377.5M$378M$405.4M$479.1M
Cash and short-term investments$398M$358.5M$350.5M$389.4M$466.1M
Income statement
20252024202320222021
Revenue$283.1M$235.1M$175.5M$134M$45.6M
Cost of revenue$32.7M$28.3M$14.2M$5.66M$1.09M
Gross profit$250.4M$206.9M$161.4M$128.4M$44.5M
Research and development expenses$32.5M$20.8M$49.6M$45M$51.1M
Selling, general and administrative expenses$101.8M$172M$195M$196.4M$171.4M
Other expenses$11.2M$18.8M$8.38M-$-1.52M$2.67M
Operating expenses$145.5M$211.6M$253.1M$239.8M$225.3M
Cost and expenses$178.1M$239.8M$267.2M$245.5M$226.3M
Interest income$13.6M$17M$17M$5.12M$530K
Interest expense$4.33M$4.83M$2.77M$0.00$0.00
Depreciation and amortization$9.27M$19.5M$11.7M$2.71M$2.76M
Ebitda$127.8M$31.7M-$-63.05M-$-103.65M-$-177.44M
Operating income$104.9M-$-4.69M-$-91.69M-$-111.47M-$-180.74M
Total other income/expenses, net$9.24M$12.1M$14.2M$5.12M$530K
Income before tax$114.2M$7.45M-$-77.47M-$-106.35M-$-180.21M
Income tax expense-$-173.04M$1.7M$550K$1.83M$760K
Net income$287.2M$5.75M-$-78.02M-$-108.18M-$-180.97M
Weighted average shares outstanding$134.4M$143.1M$143.2M$141.9M$129.4M
Weighted average diluted shares outstanding$138.7M$146.2M$143.2M$141.9M$129.4M
Balance sheet
20252024202320222021
Cash and short-term investments$398M$358.5M$350.5M$389.4M$466.1M
Net receivables$41.5M$36.5M$24.1M$13.5M$15.4M
Inventory$45.7M$39.2M$39.7M$24.8M$19.3M
Total current assets$492M$446.6M$424.8M$442.5M$513.3M
Property, plant and equipment, net$79.6M$98.9M$116.6M$8.56M$9.8M
Goodwill and intangible assets$3.76M$4.36M$4.98M$6.42M$8.4M
Long-term investments$0.00$0.00$200K$0.00$0.00
Total non-current assets$259.6M$104.1M$123.3M$28.3M$30M
Total assets$751.6M$550.6M$548.1M$470.9M$543.4M
Accounts payable$3.31M$5.19M$4.33M$3.09M$3.88M
Short-term debt$17.6M$15.1M$15.6M$940K$1.06M
Deferred revenue$3.72M$11M$4.81M$3.15M$190K
Total current liabilities$93.7M$97.8M$77.2M$46.1M$40.7M
Long-term debt$57.2M$64.3M$82M$7.15M$7.68M
Deferred revenue, non-current$12.7M$0.00$0.00$0.00$0.00
Total non-current liabilities$76.5M$75.4M$92.9M$19.3M$23.6M
Capital lease obligations$74.8M$79.4M$97.6M$8.09M$8.74M
Total liabilities$170.3M$173.2M$170.1M$65.4M$64.3M
Common stock$1.12B$1.19B$1.2B$1.19B$1.18B
Retained earnings-$-649.37M-$-936.57M-$-942.32M-$-864.3M-$-756.12M
Accumulated other comprehensive income (loss)-$-600K-$-650K-$-730K-$-1.06M-$-850K
Total equity$581.3M$377.5M$378M$405.4M$479.1M
Total investments$317.8M$275M$301.8M$295.2M$234.2M
Total debt$74.8M$79.4M$97.6M$8.09M$8.74M
Net debt-$-5.4M-$-4.06M$48.7M-$-86.08M-$-223.16M
Cash flow statement
20252024202320222021
Net income$287.2M$5.75M-$-78.02M-$-108.18M-$-180.97M
Depreciation and amortization$9.27M$19.5M$11.7M$2.71M$2.76M
Stock-based compensation$14.7M$31.6M$45.3M$32.3M$31.2M
Change in working capital-$-8.78M$5.45M-$-5.61M-$-6.82M-$-21.63M
Accounts receivable-$-4.91M-$-12.46M-$-10.61M$1.93M-$-15.41M
Inventory-$-6.46M$480K-$-15.87M-$-9.07M-$-5.64M
Accounts payable-$-1.87M$860K$1.24M-$-790K$4.08M
Net cash provided by operating activities$135.7M$44.4M-$-33.46M-$-79.53M-$-157.69M
Investments in property, plant and equipment-$-250K-$-280K-$-720K-$-290K-$-1.5M
Acquisitions, net$0.00$0.00$0.00$0.00-$-1.2M
Net cash used for investing activities-$-32.77M$39.3M-$-6.71M-$-60.63M-$-103.87M
Common stock issued$15M$0.00$0.00$0.00$196.7M
Common stock repurchased-$-98.16M-$-40.24M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-106.11M-$-49.09M-$-5.13M$2.43M$221.1M
Net change in cash-$-3.22M$34.6M-$-45.3M-$-137.73M-$-40.45M
Cash at end of period$80.2M$83.4M$48.9M$94.2M$231.9M
Operating cash flow$135.7M$44.4M-$-33.46M-$-79.53M-$-157.69M
Capital expenditure-$-250K-$-280K-$-720K-$-290K-$-1.5M
Free cash flow$135.4M$44.1M-$-34.18M-$-79.82M-$-159.19M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aurinia Pharmaceuticals Inc.

        Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

        CEO
        Kevin C. Tang
        Employees
        128
        Beta
        1.42

        Explore

        Frequently asked questions

        What is the intrinsic value of Aurinia Pharmaceuticals Inc. (AUPH)?

        Aurinia Pharmaceuticals Inc. (AUPH) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AUPH undervalued?

        AUPH trades at a price of $14.70 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.